The Colorado Chapter of the National Hemophilia Foundation (NHF Colorado) is responsible for addressing the challenges bleeding disorder patients and their families face through education, advocacy, and empowerment.
El Capítulo de Colorado de la Fundación Nacional de Hemofilia (NHF Colorado) es responsable de abordar los desafíos que enfrentan los pacientes con trastornos hemorrágicos y sus familias a través de la educación, la defensa y el empoderamiento. Visite nuestra página en español aquí.
MILE HIGH SUMMER CAMP
Mile High Summer Camp is almost here! Our inclusive camp is designed for youth aged 7-17 with bleeding disorders, offering a refreshing break from routines and a chance to connect with the community. Exciting news for Teen Leadership (14-17 years old) - they can now attend both the Teen Leadership Weekend and Mile High Summer Camp for double the fun and learning. We're introducing Bleedership in Training (BIT) this year, allowing Teen Leadership members aged 16-17 to apply and enhance their leadership skills by assisting in organizing engaging activities. Click here to apply and join us for an unforgettable experience!
Have you or a loved one been personally impacted by current legislation surrounding medical policies? We'd love to connect with you! Please click on the button below to get involved with the Chapter's advocacy efforts.
Our Mission ... In Action
We connect people in the bleeding disorder community to available, applicable resources and to one another. Through connection we don't have to go through this alone.
We fight to protect access to quality healthcare and treatments we need to live healthy lives, but we can't do it without your voice. Discover how you and your family can make a big difference by joining our advocacy efforts.
We are committed to trailblazing the way for those affected by bleeding disorders. We encourage our community members to step out into nature, to forage ahead on their own path of independence.
We are committed to educating people inside and outside the bleeding disorder community. Education is empowerment and we strive to encourage independence through learning.
Pfizer has announced positive results from their global phase 3 BASIS clinical study of marstacimab, the company’s investigational, subcutaneous therapy that targets an anticoagulant protein known as tissue factor pathway inhibitor (TFPI).
Dear National Hemophilia Foundation Community, Staff and Friends,